Latest Research And Development News

Amplia Therapeutics reported encouraging mature data from its ACCENT trial, initiated a Phase 2b pancreatic cancer study, launched an ovarian cancer trial, and refreshed its board leadership while maintaining a solid cash balance of A$24 million.

NeuroScientific Biopharmaceuticals achieved an 80% clinical response rate in fistulising Crohn’s disease patients treated under the TGA Special Access Scheme, advancing plans for Phase 2 trials and manufacturing scale-up.

Beetaloo Energy has pushed construction of its Carpentaria Gas Plant forward, maintaining schedule and budget for Q4 2026 commissioning, while its Carpentaria-5H well delivers steady gas flow with low decline rates.

LTR Pharma’s SPONTAN shows rapid absorption in Phase II interim data while securing key US commercial deals for ROXUS, setting the stage for a US market entry later this year.

Vection Technologies has turned a corner with its first full-year positive operating cash flow, underpinned by $41.5 million in customer receipts and over $17 million in new orders announced around the year-end.

Argent BioPharma has eliminated US$5.5 million in secured debt through a global licensing agreement for its CannEpil® epilepsy therapy, while completing a key acquisition and advancing clinical trials in veterinary therapeutics.

Prescient Therapeutics boosted enrolment in its PTX-100 Phase 2a trial to 28 patients and appointed Dr Rosalind Wilson as Chief Medical Officer, strengthening its clinical leadership as it advances targeted cancer therapies.

Arovella Therapeutics secured ethics approval and manufactured its first clinical batch of ALA-101, targeting blood cancers, while progressing its solid tumour program and refining autoimmune strategies. The company ended the quarter with $14.4 million in cash, supporting imminent clinical milestones.

Lumos Diagnostics reported a 6% revenue increase to US$13.2 million for FY26, driven by an 875% surge in FebriDx® sales following a pivotal CLIA waiver. The company expanded U.S. adoption to 170+ healthcare sites and secured milestone payments exceeding US$6 million.

Proteomics International Laboratories has streamlined operations, secured a key US patent for its endometriosis test, and inked a three-year exclusive distribution deal with Healius for its Promarker diagnostics in Australia.

Energy Action Limited's unaudited FY26 results show a sharp profit decline to $0.45 million on stable revenue of $12.2 million, weighed down by lower R&D incentives and higher costs.

Janus Electric has locked in A$7.7 million through a private placement to bolster its growth in the North American electric heavy vehicle market, following a surge in orders.